Dennis Carson - Dynavax Technologies Independent Director
DVAX Stock | USD 11.42 0.34 2.89% |
Director
Dr. Dennis A. Carson, M.D., serves as Independent Director of Dynavax Technologies Corporationrationration. Dr. Carson is a noted researcher in the fields of autoimmune and immunodeficiency diseases and is codiscoverer with Dr. Eyal Raz of the immunostimulatory sequences that form the basis of our technology. He has played key roles in the founding of Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr. Carson is former director of the Rebecca and John Moores Cancer Center at the University of California, San Diego and was a professor in the Department of Medicine at the University of California, San Diego since 1990. The Board believes that Dr. Carsons significant experience in research and development provides important insights for the strategy of the Company, particularly with regard to scientific opportunities for development by the Company, and qualifies Dr. Carson to be nominated as a director. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He received his M.D. from Columbia University and his B.A. from Haverford College since 1997.
Age | 71 |
Tenure | 27 years |
Professional Marks | Ph.D |
Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
Phone | 510 848 5100 |
Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0106) %, meaning that it created substantial loss on money invested by shareholders. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 19.9 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024.Similar Executives
Showing other executives | DIRECTOR Age | ||
Andreas Wicki | Pacira Pharmaceuticals | 59 | |
David Hirsch | Collegium Pharmaceutical | 47 | |
Sue Bailey | Emergent Biosolutions | 76 | |
Floyd Petersen | Amphastar P | 74 | |
Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
David Anstice | Alkermes Plc | 69 | |
Alain Schreiber | Eagle Pharmaceuticals | 58 | |
Gary Lyons | Neurocrine Biosciences | 66 | |
Michael Ross | Deciphera Pharmaceuticals LLC | 68 | |
Kenneth Pucel | Lantheus Holdings | 51 | |
Jon Duane | Ironwood Pharmaceuticals | 59 | |
Kathryn Zoon | Emergent Biosolutions | 71 | |
James Clemmer | Lantheus Holdings | 53 | |
Ronald Richard | Emergent Biosolutions | 64 | |
George Morrow | Neurocrine Biosciences | 66 | |
Sander Flaum | Eagle Pharmaceuticals | 81 | |
Richard Edlin | Eagle Pharmaceuticals | 57 | |
Robert Glenning | Eagle Pharmaceuticals | 57 | |
Terrence Blaschke | Durect | 71 | |
Paul Hastings | Pacira Pharmaceuticals | 58 | |
Mark Schobel | Aquestive Therapeutics | 61 |
Management Performance
Return On Equity | -0.0106 | ||||
Return On Asset | -0.0192 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Arnold Oronsky, Independent Chairman of the Board | ||
Francis Cano, Independent Director | ||
Daniel Kisner, Independent Director | ||
Dennis Carson, Independent Director | ||
Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
Eddie Gray, CEO and Director | ||
Peggy Phillips, Independent Director | ||
Nicole Arndt, Sr Relations | ||
Laura Brege, Director | ||
David Johnson, Chief Accounting Officer, Vice President | ||
Andrew Hack, Director | ||
John Slebir, Senior Counsel | ||
Jeff Coon, CHRO Administration | ||
Meg Smith, VP Operations | ||
Todd Lopeman, Senior Operations | ||
Stanley Plotkin, Independent Director | ||
Dan Kisner, Independent Director | ||
Riccardo Manetti, Business President | ||
Eric Frings, Site VP | ||
Natale Ricciardi, Director | ||
David Novack, Sr. VP of Operations and Quality | ||
Donn Casale, Chief Officer | ||
Kelly MacDonald, Senior CFO | ||
Paul Cox, VP Communications | ||
Dong Yu, Senior Research | ||
Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
Robert Coffman, Chief Scientific Officer and Sr. VP | ||
Justin Burgess, Principal Controller | ||
Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0106 | ||||
Return On Asset | -0.0192 | ||||
Profit Margin | (0.03) % | ||||
Operating Margin | (0.12) % | ||||
Current Valuation | 1.06 B | ||||
Shares Outstanding | 130.86 M | ||||
Shares Owned By Insiders | 0.31 % | ||||
Shares Owned By Institutions | 97.99 % | ||||
Number Of Shares Shorted | 17.97 M | ||||
Price To Earning | 6.95 X |
Pair Trading with Dynavax Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dynavax Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dynavax Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against Dynavax Stock
0.66 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
0.66 | NRSNW | NeuroSense Therapeutics | PairCorr |
0.63 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
0.57 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
0.53 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
The ability to find closely correlated positions to Dynavax Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dynavax Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dynavax Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dynavax Technologies to buy it.
The correlation of Dynavax Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dynavax Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dynavax Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dynavax Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.05) | Revenue Per Share 1.804 | Quarterly Revenue Growth (0.70) | Return On Assets (0.02) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.